Respiratory News and Research

RSS

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for orphan drug designation for ALS-886, a novel therapy to reduce and prevent tissue damage, for the treatment of Acute Respiratory Distress Syndrome (ARDS).

19 Nov 2010

Nanoparticles in everyday products can affect lungs: Study

Tiny particles used in a range of everyday products from computers to shampoo can adversely affect the lungs in very different ways, a study has shown.

18 Nov 2010

PAREXEL reaches milestone in early phase studies

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.

From Parexel 18 Nov 2010

CDC data: Adults remain unvaccinated against preventable infectious illnesses

New data from the Centers for Disease Control and Prevention (CDC) show that adults remain largely unvaccinated against preventable infectious illnesses.

18 Nov 2010

FIP's PSWC and AAPS Annual Meeting to highlight targeted inhalable dry powder HPV vaccine

New research being presented at the 2010 FIP Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition will highlight a targeted inhalable dry powder vaccine that may prove preferable in terms of needle avoidance and expected lower cost than the current commercial human papillomavirus (HPV) vaccine used throughout the world.

18 Nov 2010

Clinical trial shows dalfampridine tablets improve walking ability in MS patients

Acorda Therapeutics, Inc. today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology.

18 Nov 2010

Viruses lead to discovery of security system in host cells

Viruses have led scientists at Washington University School of Medicine in St. Louis to the discovery of a security system in host cells.

18 Nov 2010

Combination of two devices increases long-term survival in cardiac arrest patients

A combination of two devices could save the lives of several thousand cardiac arrest patients each year if implemented nationwide, suggests results of a clinical trial presented at today's American Heart Association Resuscitation Science Symposium.

17 Nov 2010

Pre-term births are leading cause of health problems in infants and cost the U.S. over $26 billion annually

The Center for Healthcare Research & Transformation (CHRT) based at the University of Michigan today released its Prematurity Issue Brief that shows pre-term births --- births at less than 37 weeks of gestation --- are the leading cause of health problems in infants and estimated to cost the U.S. more than $26 billion annually. In addition, the report shows that a black infant in Michigan is 70% more likely to be born prematurely than an infant of any other race.

17 Nov 2010

Medical Acoustics receives UB CAT/NYSTAR grant

Medical Acoustics LLC, a commercial-stage medical device company which employs acoustic technologies for diagnostic and therapeutic medical applications, today announced that it has been awarded a UB CAT/NYSTAR grant.

16 Nov 2010

National campaign to highlight significance of antibiotic resistance

Antibiotic resistance is one of the world's most pressing public health threats. To bring attention to this increasing problem, the Centers for Disease Control and Prevention and other government partners will observe its third annual Get Smart About Antibiotics Week on Nov. 15-21, 2010.

16 Nov 2010

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

Beth Israel Deaconess Medical Center (BIDMC) will join the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet), a clinical research network sponsored by the National Heart Lung and Blood Institute (NHLBI) to conduct randomized clinical trials to evaluate new and existing medications for the treatment of idiopathic pulmonary fibrosis (IPF). The network is made up of healthcare institutions from around the United States.

16 Nov 2010

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced a total of 11 ZEVALIN related data presentations (five oral, six posters) at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

15 Nov 2010

New investigational drug is well tolerated in children with nmCF

PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medicine.

15 Nov 2010

Electromed first quarter net revenues increase 29% to $4,165,000

Electromed, Inc. today announced financial results for the three months ended September 30, 2010. Net revenues for the three months ended September 30, 2010 were approximately $4,165,000, a 29% increase compared to net revenues of approximately $3,228,000 for the same period last year.

15 Nov 2010

GenturaDx to showcase IDbox molecular diagnostic system at AMP 2010

GenturaDx will display its proprietary molecular diagnostic system, the IDbox System, at the annual meeting of the Association for Molecular Pathology (AMP) in San Jose, Calif. on November 17 – 20, 2010. The IDbox System incorporates all aspects of its proprietary, real-time PCR testing from sample preparation through result generation in a single-use cassette.

15 Nov 2010

Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal

Talecris Biotherapeutics announced today the publication of combined data from two studies demonstrating that augmentation therapy with Alpha(1)-Proteinase Inhibitor (Human) (A1PI) significantly reduces lung tissue loss in patients with emphysema related to Alpha(1)-antitrypsin (AAT) deficiency.

15 Nov 2010

Researchers find structural deficits in gray matter may be associated with daytime sleepiness

Patients with obstructive sleep apnea (OSA) may blame their daytime difficulties on simple sleepiness, but new research suggests that their brains may be to blame. Specifically, their cognitive challenges may be caused by structural deficits in gray matter, brought on by the intermittent oxygen deprivation that comes with OSA. The good news is that these deficits may be partially or fully reversible with early detection and treatment, according to Italian researchers

15 Nov 2010

Cortex third quarter net loss decreases to $528,000

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $528,000, or $0.01 per share, for the quarter ended September 30, 2010, compared with a net loss applicable to common stock of approximately $3,243,000 or $0.06 per share, for the prior year quarter.

12 Nov 2010

Plant-based respiratory allergies on the rise due to climate change

Bad news for 35 million allergy sufferers - ragweed, fungal spores and poison ivy are thriving due to rising carbon dioxide levels. At the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov. 11-16, allergists and scientists discussed the effects of rising CO2 levels and a changing climate on plant biology and public health.

12 Nov 2010